REVIEW article
Front. Cell Dev. Biol.
Sec. Cell Adhesion and Migration
Volume 13 - 2025 | doi: 10.3389/fcell.2025.1671152
This article is part of the Research TopicRegulation of Permeability of Tight JunctionsView all 5 articles
PROBIOTICS AND THE INTESTINAL TIGHT JUNCTION BARRIER FUNCTION
Provisionally accepted
- University of Nebraska Medical Center, Omaha, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Disruption of the intestinal epithelial tight junction (TJ) barrier is a key pathogenic factor in numerous gastrointestinal (GI) disorders, including inflammatory bowel disease, irritable bowel syndrome, necrotizing enterocolitis, and enteric infections. The gut microbiota plays a pivotal role in regulating epithelial integrity, and emerging evidence highlights the therapeutic potential of probiotics in preserving or restoring TJ barrier function. This review summarizes the current literature on the protective effects of probiotics in modulating intestinal epithelial TJ barrier function. Specific strains of Lactobacillus, Bifidobacterium, Escherichia coli Nissle 1917, Bacillus subtilis, and Saccharomyces boulardii have been shown to enhance barrier integrity in cell culture, animal models, and in some clinical settings. These probiotics exert their effects through diverse mechanisms, including the upregulation of TJ proteins (e.g., occludin, claudins, ZO-1), suppression of proinflammatory cytokines, inhibition of NF-κB, myosin light chain kinase (MLCK) and MAPK signaling pathways, and activation of host pattern recognition receptors such as TLR-2 and PPARγ. Moreover, several studies highlight the strain-specific nature of these effects, underscoring the importance of identifying and characterizing individual probiotic strains for therapeutic use. Taken together, the data reviewed here support the potential of probiotics as adjunctive or preventive therapies targeting epithelial barrier dysfunction in a range of GI diseases. However, further mechanistic studies, clinical trials, and standardization of probiotic formulations are needed to translate these findings into effective, personalized interventions. This review highlights both the promise and complexity of probiotic-mediated intestinal barrier regulation and provides new insight for future research in this rapidly evolving field.
Keywords: Probiotics1, tight junctions2, intestinal permeability3, Intestinal inflammation4, probioticsignaling5
Received: 22 Jul 2025; Accepted: 20 Oct 2025.
Copyright: © 2025 Ferris, Subitoni Antonio and Al-Sadi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Rana Al-Sadi, ralsadi@unmc.edu
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.